Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) on January 31 and set a price target of $190.00. The company’s shares closed last Friday at ...

Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment ...

Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $185 from $170 and keeps an Overweight rating on the shares. The share price is up 32% from 12-month lows in early October ...

Neurocrine Biosciences stock opened at $150.10 on Tuesday. The stock has a market cap of $15.20 billion, a price-to-earnings ratio of 40.24 and a beta of 0.33. The company’s 50-day moving ...

Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market cap of $15.20 billion, a P/E ratio of 40.24 and a beta of 0.33. Analyst Upgrades and ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target of $184.00. The company’s shares closed yesterday at ...

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff ...